Phase I study to assess biodistribution of CB307, a trispecific Humabody® targeting CD137, PSMA, and human serum albumin with 89Zr-CB307 PET
Posters & Publications
03 July 2024
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum
11 June 2024
Design of crosslinking antibodies for T-Cell activation: Experimental and computational analysis of PD-1/CD137 bispecific agents
10 April 2024
CB307: A dual targeting costimulatory Humabody VH therapeutic for treating PSMA-positive tumors
10 April 2024
CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumors
10 April 2024
CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumors
05 January 2024
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents
20 April 2023
CB307: A novel targeted CD137 agonist for enhancement of immune cell responses to PSMA+ tumors
12 April 2022
CB307: A novel selective CD137 agonist for enhancing immune cell responses to PSMA+ tumors
12 April 2022
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumors (POTENTIA)
31 December 2021
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
12 May 2021
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
12 May 2021
Humabody® VH : A versatile platform for generation of novel therapeutics (PEGS virtual poster 2021)
16 April 2021
Fully Human Antibody VH Domains to Generate Mono and Bispecific CAR to Target Solid Tumors
10 April 2021
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumors (POTENTIA)
11 November 2020
CB307: A Novel T-cell Costimulatory Humabody® VH Therapeutic for PSMA-positive Tumours (PEGS 2020 Poster)
14 May 2020
Development of a Stable Spray Dried Formulation of an IL-17A Humabody® VH Domain
15 January 2020
Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
11 November 2019
Diverse Human VH Antibody Fragments with Bio-therapeutic Properties from
the Crescendo Mouse
12 April 2019
CB307 A Novel T cell Costimulatory Humabody® VH Therapeutic for PSMA-positive Tumors (PEGS 2019 Poster)
12 November 2018
Multifunctional Biologics based on In Vivo Matured 100% Human VH Domains (PEGS 2018 Poster)
12 November 2018
Multifunctional Humabody® Biologics for Immune-Oncology based on In Vivo Matured Fully Human VH (PEGS 2018 Poster)
20 March 2018
Multifunctional Biologics for Targeted T cell Therapy based on Humabody® VH Domains (AACR 2018 Poster)
09 March 2015
Nature Biopharma Dealmakers: Humabody® Fragments: small and perfectly formed